GO
Loading...

Kate Kelly

CNBC Reporter

Kate Kelly joined CNBC in May 2010 as a reporter focusing on hedge funds and Wall Street. She appears during CNBC's business day programming and contributes to CNBC.com.

Previously, Kelly was a staff reporter for The Wall Street Journal, where she spent a decade. She covered numerous firms for the Journal including Goldman Sachs and Morgan Stanley as well as the movie business and the New York Stock Exchange. Before joining the Journal in 2001, she was a writer and reporter for Time magazine and, before that, a reporter at The New York Observer.

She has won a number of prestigious awards, including two Gerald Loeb Awards, four awards from the Society of American Business Editors and a Livingston Award for Young Journalists in the national reporting category.

She also has been honored by the Newswomen's Club of New York, the Medill School of Journalism and the New York City Deadline Club. She is the best-selling author of "Street Fighters: The Last 72 Hours of Bear Stearns, the Toughest Firm on Wall Street" and she released her second book, "The Secret Club That Runs The World: Inside the Fraternity of Commodity Traders," in June 2014.

Kelly holds a bachelor's degree from Columbia College at Columbia University.

Follow Kate Kelly on Twitter @katekellycnbc.

More

  • GM's IPO Likely to Price at $33 a Share, Top of Range Wednesday, 17 Nov 2010 | 12:57 PM ET
    Jon Lauckner, General Motors' Vice President of Global Product Planning, speaks at the Detroit Hamtramck Assembly Plant. GM announced that they will invest $336 million to build the new Chevrolet Volt extended range electric vehicle at the plant.

    Unless stock markets move sharply this afternoon, GM shares are likely to be priced at $33 apiece later Wednesday—the top of their announced range—as part of the company’s IPO, according to people with knowledge of the matter.

  • GM Headquarters

    Underwriters of GM’s hotly anticipated initial public offering are raising the deal’s price to $32 to $33 per share Monday night, someone familiar with the matter told CNBC.

  • A spokesman for FrontPoint Partners, the Connecticut hedge fund entangled in a criminal and civil probe of alleged insider trading in shares of a biotech company, has identified health-care analyst Chip Skowron as the employee who participated in the scheme.

Shark Tank: Outside the Tank

Restaurant Startup: Quick Bites

The Biz Fix with Marcus Lemonis

Ask the Car Chasers

American Greed: Don't Get Taken